Navigation Links
Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System
Date:2/29/2012

ALISO VIEJO, Calif. and LEXINGTON, Mass., Feb. 29, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) and Concert Pharmaceuticals, Inc. announced today that they have entered into an exclusive license agreement that provides Avanir worldwide rights to develop and commercialize Concert's deuterium-modified dextromethorphan (d-DM) for the potential treatment of neurological and psychiatric disorders.  The agreement includes the rights to multiple deuterium-modified dextromethorphan compounds.

Under the terms of the agreement, Concert will receive an upfront payment and is eligible to receive additional milestone payments upon achievement of certain predefined clinical, regulatory and commercial targets as well as tiered royalties on worldwide sales of products containing d-DM.  Avanir will have overall responsibility for research, development and commercialization of d-DM.  Concert will provide manufacturing support for investigational new drug enabling studies.

"Concert's DCE Platform (Deuterated Chemical Entity Platform) has produced several deuterium-modified dextromethorphan compounds that we believe may provide therapeutically effective levels of dextromethorphan, potentially without the need for an enzyme inhibitor such as quinidine," said Greg Flesher, senior vice president of corporate development and chief business officer of Avanir Pharmaceuticals.  "As part of our portfolio strategy, we intend to explore the utility of d-DM in neurological and psychiatric disorders where dual NMDA antagonists and sigma-1 agonists may be beneficial."

"We are very pleased to enter into this collaboration with Avanir, who we believe has the unique expertise to best maximize the broad clinical potential of d-DM.  Avanir's knowledge of dextromethorphan-based therapeutics and their proven track record to bring drugs to the market make th
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.; Concert Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  The World MS Day campaign led by the ... awareness of multiple sclerosis and those living with MS ... will move us closer a world free of MS. ... including the National MS Society, have events and planned ... MS Day campaign theme is "access." Whether it is ...
(Date:5/27/2015)...  A special presentation at Digestive Disease Week ... successful experience using  Stretta Therapy  to ... Ronnie Fass , MD, of ... reviewed clinical data on Stretta. Expert panelists then ... Stretta has helped them treat.      Dana ...
(Date:5/27/2015)... Nev. , May 27, 2015  PDL BioPharma, ... John P. McLaughlin , the company,s president and ... Global Healthcare Conference next week in New York City.  ... Wednesday, June 3, 2015 at 11:30 a.m. EDT. ... of the presentation, go to the Company,s website at ...
Breaking Medicine Technology:People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis 2People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis 3People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis 4People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis 5DDW Presentation Examines Stretta As A Versatile And Effective GERD Treatment For Multiple Patient Populations 2DDW Presentation Examines Stretta As A Versatile And Effective GERD Treatment For Multiple Patient Populations 3PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference 2
... Agendia, a commercial-stage molecular cancer diagnostics ... Breast Cancer Conference (2011) Expert Panel,s recommendations highlight the ... particular biological subtype of their tumor - in guiding ... panel, "it is no longer tenable to consider breast ...
... -- Winner Medical Group Inc. (Nasdaq: WWIN ; "Winner ... disposables and non-woven fabric made from 100% natural PurCotton® products in ... June 30, 2011. Fiscal Third ... (in millions of USD, except per share data)Q3 , FY2011 ...
Cached Medicine Technology:International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 2International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 3Winner Medical Reports Third Quarter Fiscal 2011 Results 2Winner Medical Reports Third Quarter Fiscal 2011 Results 3Winner Medical Reports Third Quarter Fiscal 2011 Results 4Winner Medical Reports Third Quarter Fiscal 2011 Results 5Winner Medical Reports Third Quarter Fiscal 2011 Results 6Winner Medical Reports Third Quarter Fiscal 2011 Results 7Winner Medical Reports Third Quarter Fiscal 2011 Results 8Winner Medical Reports Third Quarter Fiscal 2011 Results 9Winner Medical Reports Third Quarter Fiscal 2011 Results 10Winner Medical Reports Third Quarter Fiscal 2011 Results 11Winner Medical Reports Third Quarter Fiscal 2011 Results 12Winner Medical Reports Third Quarter Fiscal 2011 Results 13Winner Medical Reports Third Quarter Fiscal 2011 Results 14Winner Medical Reports Third Quarter Fiscal 2011 Results 15
(Date:5/27/2015)... CompanionDx announced that its ... analysis in personalized cancer therapy: Non-small cell lung cancer ... of Clinical Oncology (ASCO) as part of their annual ... The molecular and clinical data used for the study ... The study reports improved patient outcomes from a preliminary ...
(Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
(Date:5/27/2015)... Texas (PRWEB) May 27, 2015 ... the current state of the Omega-3 industry. The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ... Gc Rieber Oils, Camanchaca Fishing Company, Seadragon Marine ...
(Date:5/27/2015)... 2015 SonarMD, LLC, recently ... a first-of-its kind, cloud-based algorithmic process for ... chronic gastrointestinal disease. , Developed by noted ... allows physicians to monitor their patients’ health ... of electronic health assessment surveys. Using nationally ...
(Date:5/27/2015)... MD (PRWEB) May 27, 2015 “Heroin has ... that’s where our overdoses are coming from,” says Harford County ... on May 8th. In the surging heroin related incidents ... pushing for prevention education to prevent heroin addiction and subsequent ... a possession charge. Drug Rehab Baltimore is a drug and ...
Breaking Medicine News(10 mins):Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3
... THIN CHILDREN MAY HAVE POORER LUNG FUNCTION ,A ... through midlife may be influenced by several factors, including birth ... United Kingdom analyzed health data from 252 patients, all aged ... the patients at age 49 to 51. Results showed that ...
... A minimally invasive surgical approach developed by head ... of Medicine has been cleared by the U.S. Food ... (Intuitive Surgical, Inc., Sunnyvale, California) has been cleared for ... select malignant tumors in adults. Drs. Gregory S. ...
... Energy and Commerce as part of an investigation into preventable ... report recommending further restrictions regarding duty hours for resident physicians ... safety, according to an article published in the January issue ... (JACR). In 2003, the Accreditation Council for ...
... sexual arousal, whereas in men, the responses of the ... other, according to Assistant Professor Meredith Chivers, from Queen,s ... Seto, Martin Lalumire, Ellen Laan, and Teresa Grimbos. Their ... and physiological measures of sexual arousal in men and ...
... osteoarthritis (OA) accounts for more disability in the elderly than ... other health benefits, can increase stresses on the joints of ... issue of PM&R: The journal of injury, function and ... ankle joint motions of running barefoot versus running in modern ...
... researchers halted the growth of blood vessels that tumors ... in the Journal of Experimental Medicine ( ... its effects on neuronal growth, the team found that ... human blood vessels. By diminishing {delta}-catenin expression, the team ...
Cached Medicine News:Health News:News briefs from the January issue of Chest 2Health News:FDA clears TransOral robotic surgery developed at Penn 2Health News:FDA clears TransOral robotic surgery developed at Penn 3Health News:Institute of Medicine recommends stricter resident duty hour regulations to prevent medical errors 2Health News:Women's bodies and minds agree less than men's on what's sexy 2Health News:Running shoes may cause damage to knees, hips and ankles 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: